From MarketBeat:



Protagonist Therapeutics was upgraded by StockNews.com from a “sell” rating to a “hold” rating, receiving several buy ratings from other research firms. Protagonist Therapeutics stock traded up $0.63 during trading on Monday, reaching $22.24 and last posted its quarterly earnings data, reporting ($0.58) EPS for the quarter. The company is predicted to post -1.72 EPS for the current year. Institutional investors including BVF Inc. IL, State Street Corp, Cowen AND Company LLC, Braidwell LP, and RTW Investments LP have added or reduced their stakes in the business, owning 98.63% of the stock combined. The company develops peptide-based drugs for hematology, blood disorders, inflammatory, and immunomodulatory diseases, as well as developing injectable hepcidin mimetic and an orally delivered investigational drug.

While Protagonist Therapeutics has a “Buy” rating among analysts, top-rated analysts recommend five other stocks as better buys. One can take a free report offering 10 simple stocks that can help beginning investors build long-term wealth.



Read more: Protagonist Therapeutics (NASDAQ:PTGX) Raised to “Hold” at StockNews.com